ZnPcH1-PDT对CNE1细胞增殖抑制作用研究

目的本文探讨新型酞菁类光敏剂ZnPcH1介导的光动力疗法(ZnPcH1-PDT)对鼻咽癌细胞的杀伤作用。方法采用人鼻咽癌CNE1细胞作为研究对象。应用MTT比色法和细胞集落形成实验检测PDT对细胞的杀伤作用。结果 ZnPcH1-PDT对鼻咽癌CNE1细胞有杀伤作用,呈量效关系(P<0.05)。结论 ZnPcH1-PDT能够有效地抑制鼻咽癌细胞的增殖,且呈量效关系。     

MAPK/ERK信号通路在益气解毒方水提物诱导鼻咽癌细胞凋亡中的作用

目的研究益气解毒方水提物对鼻咽癌细胞凋亡的影响,并从MAPK/ERK信号通路探讨其诱导凋亡的作用机制。方法 CCK-8法检测益气解毒方水提物对CNE1、CNE2细胞增殖的影响;Hoechst 33342染色法、JC-10染色法、荧光双染流式细胞仪检测其对CNE1、CNE2细胞凋亡的影响;Western blot法检测其对CNE1、CNE2细胞蛋白表达的影响。结果益气解毒方水提物能抑制CNE1、CNE2细胞增殖(P<0.05)、诱导凋亡(P<0.05);药物作用48 h后,Survivin、XIAP、Bcl-2表达下降,Bax表达上升,MAPK/ERK信号通路关键蛋白p-c-Raf、p-MEK、p-ERK表达下降(P<0.05);在此基础上,加入激活剂ISO和益气解毒方水提物后,与单用益气解毒方水提物相比,p-c-Raf、p-MEK、p-ERK1/2表达上调,Survivin、XIAP、Bcl-2表达增加,Bax表达下降,促凋亡效应也降低(P<0.05)。结论益气解毒方水提物可诱导鼻咽癌细胞凋亡,该效应与其抑制MAPK/ERK信号通路关键蛋白p-c-Raf、p-MEK、p-ERK1/2表达,进而下调Survivin、XIAP、Bcl-2表达,上调Bax表达有关。     

人鼻咽癌细胞CNE_2对各种抗肿瘤药敏感性试验

目的 :了解人鼻咽癌细胞CNE2 对各种抗肿瘤化疗药的敏感性。方法 :体外噻唑蓝还原 (MTT)试验法。结果 :1 3种抗肿瘤药对CNE2 细胞均有明显的杀伤作用 ,其中有 1 0种抗肿瘤药的半数抑制浓度 (IC50 )在 2 0 μg/ml以下 ,另 3种药的IC50 为 2 7.3～ 53.91 μg/ml。结论 :人鼻咽癌细胞CNE2 对临床应用的各类抗肿瘤药是敏感的。     

二烯丙基二硫下调cyclin D1和CDK4的表达诱导人鼻咽癌CNE2细胞G_1期阻滞

目的研究二烯丙基二硫(DADS)对人鼻咽癌CNE2细胞的影响及其分子机制。方法采用MTT法检测DADS对CNE2细胞增殖抑制作用;流式细胞术分析DADS对CNE2细胞周期分布的影响;运用RT-PCR和Western blot方法分析DADS作用CNE2细胞后,cyclin D1和CDK4的表达变化。结果 MTT结果显示,不同浓度DADS(90、140、240、400μmol·L-1)处理CNE2细胞48h后,生长抑制率分别为4.0%、13.8%、25.8%、51.2%;流式细胞术分析显示,DADS阻滞CNE2细胞于G1期,并呈浓度依赖性;RT-PCR和Western blot结果表明,细胞周期调控基因cyclinD1、CDK4表达下调。结论 DADS对CNE2细胞的增殖抑制作用与其阻滞细胞G1期有关,并且可能是通过抑制cyclin D1、CDK4的表达使CNE2细胞阻滞于G1期。     

染料木素对人鼻咽癌CNE1细胞生长的抑制作用及靶点预测

目的:研究染料木素对人鼻咽癌CNE1细胞生长的抑制作用并预测其可能的作用靶点.方法:采用CCK-8法检测0(空白对照)、12.5、25、50、100、150μmol/L染料木素分别作用24、48、72 h对CNE1细胞增殖的影响;分别采用流式细胞术检测0(空白对照)、15、30、60μmol/L染料木素作用24 h对C...     

组织桥接整合因子 1、Ⅰ型胶原蛋白基因、核转运蛋白基因 2与三阴性乳腺癌术后复发关系

目的探究组织桥接整合因子 1(BIN1)、Ⅰ型胶原蛋白基因(COL1A1)、核转运蛋白基因 2(KPNA2)表达与三阴性乳腺癌(TNBC)术后复发关系及联合检测意义。方法选取 2019年 5月至 2020年 5月上海市第八人民医院行手术治疗的 TNBC病人 80例,根据术后 2年是否复发分为复发组、未复发组,比较两组临床资料、组织 BIN1、COL1A1、KPNA2基因表达,复发的相关影响因素采用单因素与多因素 logistic回归分析,组织 BIN1、COL1A1、KPNA2基因表达预测术后复发的价值采用受试者操作特征曲线(ROC曲线)分析,组织 BIN1、COL1A1、KPNA2基因表达与复发时间关系采用 Pearson分析,比较不同组织 BIN1、COL1A1、KPNA2基因表达病人无复发生存期( RFS)。结果复发组 T分期、 N分期与未复发组比较,差异有统计学意义( P<0.05);复发组组织 BIN1 mRNA表达为 0.24±0.07,低于未复发组的 0.35±0.10(P<0.05),复发组组织 COL1A1 mRNA、KPNA2 mRNA表达分别为 2.07±0.62、2.91±0.84,高于未复发组的 1.48±0.43、1.85±0.60(P<0.05); T分期、 N分期、 COL1A1 mRNA、KPNA2 mRNA均是复发相关独立危险因素, BIN1 mRNA是复发相关独立保护因素( P<0.05); BIN1 mRNA、COL1A1 mRNA、KPNA2 mRNA的 AUC分别为 0.76、0.80、0.78,三者联合的 AUC为 0.94;BIN1 mRNA与复发时间呈负相关(r=-0.79,P<0.001),COL1A1 mRNA、KPNA2 mRNA与复发时间呈正相关(r=0.77、0.78,均 P<0.001); BIN1 mRNA高水平病人 RFS长于低水平病人, COL1A1 mRNA、KPNA2 mRNA高水平病人 RFS短于低水平病人(P<0.05)。结论 BIN1 mRNA、COL1A1 mRNA、KPNA2 mRNA与 TNBC术后复发风险、复发时间有关,联合检测可作为早期预测术后复发的一个可靠方案,为临床治疗提供重要的参考信息。     

灵芝三萜组分GLE的体内外抗肿瘤作用

目的:评价灵芝三萜组分GLE的体内外抗肿瘤作用。方法:建立小鼠S180实体瘤和腹水瘤两种模型,观察GLE对实体瘤抑瘤率和腹水瘤生命延长率的影响;采用MTT法检测GLE对人鼻咽癌细胞CNE1和CNE2的体外抗肿瘤活性。结果:3个剂量(125,250,500 mg.kg-1)GLE对S180实体瘤小鼠均具有一定的抑制作用(P<0.05),500 mg.kg-1组的瘤重抑制百分率达51.4%;对S180腹水瘤小鼠具有明显的延长存活期作用,500 mg.kg-1组的生命延长率为52.0%(P<0.05);体外对人鼻咽癌低分化细胞CNE2有一定的抑制作用。结论:GLE对小鼠肉瘤S180及人鼻咽癌低分化细胞CNE2的生长有一定的抑制作用。     

神经酰胺诱导鼻咽癌细胞凋亡

目的　了解第二信使神经酰胺信号转导对鼻咽癌细胞生长的影响。方法　采用MTT法检测神经酰胺对鼻咽癌细胞株 (CNE 2 )增殖的抑制作用。光镜观察、荧光染色、流式细胞术检测细胞凋亡改变。Westernblot法检测p2 1WAF1的表达。结果　神经酰胺在 6 2 5、12 5、2 5、5 0 μm浓度下 ,对CNE 2细胞生长有明显的抑制作用 ,流式细胞仪检测发现亚G1峰出现 ,荧光染色可见核荧光强度增加、核片段化和凋亡小体。p2 1WAF1蛋白表达明显上调。结论　神经酰胺能诱导鼻咽癌细胞株CNE 2凋亡 ,且上调 p2 1WAF1蛋白表达。p2 1WAF1可能是神经酰胺诱导鼻咽癌细胞凋亡中起作用的因素之一。     

胶原蛋白 Ⅴ型 2链对胃癌细胞增殖、迁移和侵袭及肿瘤生长的调控作用

目的探究胶原蛋白 Ⅴ型 2链( COL5A2)对胃癌细胞增殖、迁移和侵袭及肿瘤生长的调控作用。方法于 2022年 1―3月开展研究,基于 TCGA数据库分析 COL5A2在胃癌组织、正常组织中的表达差异, COL5A2对胃癌分期的作用及对病人预后的价值。荧光定量聚合酶链式反应( qRT-PCR)、蛋白质印迹法( WB)检测正常人胃黏膜上皮细胞 GES-1、胃癌细胞 MGC-803、 MKN-45、SGC7901中 COL5A2的表达。慢病毒介导稳定转染 shRNA-COL5A2、shRNA、NC的 MKN-45细胞。克隆形成实验、细胞计数试剂盒( CCK8)、 5-乙炔基 -2''-脱氧尿苷( EdU)染色检测细胞的增殖;碘化丙啶( PI)染色检测细胞周期分布; Transwell实验、伤口愈合实验检测细胞的迁移、侵袭能力;裸鼠成瘤实验检测肿瘤的生长;免疫组织化学实验检测肿瘤组织 PCNA蛋白。结果胃癌组织 COL5A2相对表达量为 4.74±0.45,显著高于正常组织的 2.53±0.26(P<0.05)与正常组织相比,胃癌组织中 COL5A2升高,与病人临床分期、预后差有关。 GES-1组 COL5A2相对表达量为 0.25±0.04,显著,低于胃癌细胞中 MGC-803组0.47±0.05、MKN-45组 0.72±0.08、SGC7901组 0.54±0.04(P<0.05),其中 MKN-45升高幅度最大。与 shRNA组细胞相比, shRNA-COL5A2组细胞 COL5A2表达降低,细胞的克隆形成数、在 48、72 h的活性、 EdU阳性率、迁移和侵袭数量、划痕愈合率均降低,细胞周期阻滞 G1/S期, CyclinD1和 CDK4表达降低( P<0.05)。异种移植裸鼠成瘤的体积、质量均降低,肿瘤 PCNA表达也降低。结论 COL5A2在胃癌中高表达,下调 COL5A2抑制癌细胞增殖、迁移侵袭及肿瘤的生长。     

去甲斑蝥素诱导人鼻咽癌细胞CNE1凋亡的实验研究

目的检测去甲斑蝥素对人鼻咽癌细胞CNE1增殖、凋亡的影响,为临床应用NCTD治疗鼻咽癌细胞提供实验基础。方法体外常规培养CNE1细胞用于实验,经NCTD作用后,采用MTT比色法检测细胞增殖情况,流式细胞仪观察鼻咽癌细胞凋亡、细胞周期。结果 NCTD对鼻咽癌细胞的生长有明显的抑制作用,呈剂量依赖性,与对照组比较差异有统计学意义(P<0.01);NCTD可剂量和时间依赖性地诱导肿瘤细胞凋亡;NCTD可剂量依赖性地诱导肿瘤细胞周期发生改变,将鼻咽癌细胞阻滞在G2期。结论 NCTD对体外培养的CNE1细胞的生长有明显抑制作用和诱导凋亡的作用。     

Sulfation of iodothyronines by human sulfotransferase 1C1 (SULT1C1)*

Sulfation is an important component of human thyroid hormone metabolism. The role of the human sulfotransferase 1C1 (SULT1C1) is not known. Because SULT1C1 is present in the adult thyroid, intra-thyroidal sulfation of thyroid hormones and their metabolites might occur. We tested this hypothesis by determining the ability of recombinant human SULT1C1 to catalyze iodothyronine sulfation. Apparent K(m) values for 3,3',5-triiodothyronine (T(3)), 3, 3'-diiodothyronine (3,3'-T(2)), 3',5',3-triiodothyronine (rT(3)), and 3,3',5,5'-tetraiodothyronine (T(4)) with SULT1C1 were 28.7, 10.3, 10.2, and 59.3 microM, respectively. Thermal stability and responses to inhibitors also were tested with T(3) as the substrate. Enzyme aliquots were measured simultaneously to determine SULT1C1 substrate preferences at optimal iodothyronine concentrations. SULT1C1 activity obtained with T(3) was used as 100%, and the activities with 3,3'-T(2), rT(3), T(4), and 3,5-diiodothyronine (3, 5-T(2)) were 614, 314, 25, and 4%, respectively. We report for the first time the characterization of human SULT1C1 with T(3) and the preferences of the enzyme for various iodothyronines. The presence of SULT1C1 in the adult thyroid gland raises the possibilities that the enzyme can contribute to intraglandular thyroid hormone processing and iodide reutilization.     

Preferential induction of CYP1A1 and CYP1B1 in CCSP-positive cells.

Both benzo[a]pyrene (BaP) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) are potent ligands of aryl hydrocarbon receptors (AhR). Although animal studies indicate that both compounds induce pathological changes in the peripheral lung, the specific cell type involved remains unclear. Clara cells, expressing Clara cell specific protein (CCSP) and abundant in cytochrome P450, are nonciliated bronchiolar epithelial cells in the peripheral lung. Here we explore the hypothesis that CCSP-positive Clara cells are highly responsive to AhR ligands and are the primary cell type involved in BaP- and TCDD-induced toxicities. The responsiveness to AhR ligands was evaluated by measuring the respective mRNA and protein levels of cytochrome P450 1A1 (CYP1A1) and 1B1 (CYP1B1) using real-time RT-PCR and immunocytochemistry assays. Two in vitro models were used: primary cultures of human small airway epithelial (SAE) cells and rat lung slice cultures. In the presence of calcium, human SAE cells differentiated into CCSP-positive cells. BaP- and TCDD-induced mRNA and protein levels of CYP1A1 and CYP1B1 levels were significantly elevated in CCSP-positive cell cultures. Similarly, AhR mRNA and protein levels were increased in CCSP-positive cell cultures, as determined by real-time RT-PCR and Western blot analysis. When rat lung slice cultures were treated with BaP or TCDD for 24 h, CYP1A1 and CYP1B1 proteins were strongly induced in Clara cells. These results indicate that, in the peripheral lung of both rats and humans, CCSP-positive cells (Clara cells) may be more sensitive to AhR ligands than other cell types.     

Influence of genetic polymorphisms of CYP1A1 and GSTM1 on the urinary levels of 1-hydroxypyrene

The aim of the present study is to evaluate the influence of the genetic polymorphism of two enzymes involved in the biotransformation of xenobiotics, cytochrome P450 1A1 (CYP1A1) and glutathione-S-transferase M1 (GSTM1), on the urinary levels of 1-hydroxypyrene (1-OH-P) in workers exposed to polycyclic aromatic hydrocarbons (PAHs) and in unexposed workers (controls). The study group consisted of 30 controls recruited among employees of a service company and 171 PAHs-exposed workers from two electric steel plants and an iron foundry (all males, ranging between 18 and 60 years of age). Determination of airborne PAHs and urinary 1-OH-P was performed by high-performance liquid chromatography (HPLC) with fluorimetric detection. Polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) was used to determine the genetic polymorphisms of CYP1A1 (CYP1A1*2A and CYP1A1*2B) and GSTM1. No influence of the genetic polymorphism of CYP1A1 and GSTM1 on the urinary levels of 1-OH-P was observed in this study.     

Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse

Crossing the Cyp1a1/1a2(-/-) double-knockout mouse with the Cyp1b1(-/-) single-knockout mouse, we generated the Cyp1a1/1a2/1b1(-/-) triple-knockout mouse. In this triple-knockout mouse, statistically significant phenotypes (with incomplete penetrance) included slower weight gain and greater risk of embryolethality before gestational day 11, hydrocephalus, hermaphroditism, and cystic ovaries. Oral benzo[a]pyrene (BaP) daily for 18 days in the Cyp1a1/1a2(-/-) produced the same degree of marked immunosuppression as seen in the Cyp1a1(-/-) mouse; we believe this reflects the absence of intestinal CYP1A1. Oral BaP-treated Cyp1a1/1a2/1b1(-/-) mice showed the same "rescued" response as that seen in the Cyp1a1/1b1(-/-) mouse; we believe this reflects the absence of CYP1B1 in immune tissues. Urinary metabolite profiles were dramatically different between untreated triple-knockout and wild-type; principal components analysis showed that the shifts in urinary metabolite patterns in oral BaP-treated triple-knockout and wild-type mice were also strikingly different. Liver microarray cDNA differential expression (comparing triple-knockout with wild-type) revealed at least 89 genes up- and 62 genes down-regulated (P-value < or = 0.00086). Gene Ontology "classes of genes" most perturbed in the untreated triple-knockout (compared with wild-type) include lipid, steroid, and cholesterol biosynthesis and metabolism; nucleosome and chromatin assembly; carboxylic and organic acid metabolism; metal-ion binding; and ion homeostasis. In the triple-knockout compared with the wild-type mice, response to zymosan-induced peritonitis was strikingly exaggerated, which may well reflect down-regulation of Socs2 expression. If a single common molecular pathway is responsible for all of these phenotypes, we suggest that functional effects of the loss of all three Cyp1 genes could be explained by perturbations in CYP1-mediated eicosanoid production, catabolism and activities.     

Crystal structure of 1:1 complex of barbital with 1-methylimidazole.

The prediction of a strong hydrogen-bonding interaction between barbital and 1-methylimidazole was confirmed. Two crystal complexes were obtained, 1:1 and 2:1, and the X-ray structure was determined for the 1:1 complex, which is monoclinic, space group P21/c, with a = 12.236(3) A, b = 11.332(4) A, c = 12.495(4) A, and beta = 120.67(1) degrees. The structure contains disk-shaped hydrogen-bonded tetramers with two molecules of each kind. There is a short NH...N hydrogen bond (2.82 A) in which barbiturate provides the NH donor.     

Inhibitors of aldo-keto reductases AKR1C1-AKR1C4

The AKR1C aldo-keto reductases (AKR1C1-AKR1C4) are enzymes that interconvert steroidal hormones between their active and inactive forms. In this manner, they can regulate the occupancy and trans-activation of the androgen, estrogen and progesterone receptors. The AKR1C isoforms also have important roles in the production and inactivation of neurosteroids and prostaglandins, and in the metabolism of xenobiotics. They thus represent important emerging drug targets for the development of agents for the treatment of hormone-dependent forms of cancer, like breast, prostate and endometrial cancers, and other diseases, like premenstrual syndrome, endometriosis, catamenial epilepsy and depressive disorders. We present here the physiological roles of these enzymes, along with their structural properties and an overview of the recent developments regarding their inhibitors. The most important strategies of inhibitor design are described, which include the screening of banks of natural compounds (like cinnamic acids, flavonoids, jasmonates, and related compounds), the screening of and structural modifications to non-steroidal anti-inflammatory drugs, the substrate-inspired design of steroidal and nonsteroidal inhibitors, and computer-assisted structure-based inhibitor design.     

人细胞色素P450 1A1与谷胱甘肽S-转移酶的融合蛋白及其抗体的制备

采用融合蛋白技术原核表达CYP1A1（第241-381个氨基酸）与谷胱甘肽S-转移酶（GST）的融合蛋白作为抗原,用于制备CYP1A1多克隆抗体. 根据正反重组质粒pGEX/1A1表达的融合蛋白大小不同的原理,直接表达筛选得到正向重组质粒pGEX/1A1. 通过优化表达条件, 提高了目的蛋白的表达水平. 包涵体蛋白经制备型聚丙烯酰胺凝胶电泳（PAGE）分离, 获含纯化融合蛋白GST-1A1的PAGE凝胶. 直接用含GST-1A1的凝胶悬液免疫BALB/c小鼠,自腹水中获取CYP1A1多克隆抗体（1A1pAb）. 1A1pAb用切胶纯化的融合蛋白GST-2B6交叉吸收,蛋白A- Sepharose亲和层析柱来纯化. 用切胶纯化的融合蛋白GST-1A1及GST-2B6的免疫印迹反应初步鉴定1A1pAb的特异性. 纯化的1A1pAb对融合蛋白GST-1A1反应特异性较强,但仍对GST-2B6有弱交叉反应. 在实际应用中可根据反应强度来加以区分.     

In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1

The main objective of the study was to examine the biotransformation of the anticancer drug imatinib in target cells by incubating it with oxidoreductases expressed in tumor cells. The second objective was to obtain an in silico prediction of the potential activity of imatinib metabolites. An in vitro enzyme kinetic study was performed with cDNA expressed human oxidoreductases and LC-MS/MS analysis. The kinetic parameters (Km and Vmax) were determined for six metabolites. A molecular modeling approach was used to dock these metabolites to the target Abl or Bcr-Abl kinases. CYP3A4 isozyme showed the broadest metabolic capacity, whereas CYP1A1, CYP1B1 and FMO3 isozymes biotransformed imatinib with a high intrinsic clearance. The predicted binding modes for the metabolites to Abl were comparable to that of the parent drug, suggesting potential activity. These findings indicate that CYP1A1 and CYP1B1, which are known to be overexpressed in a wide range of tumors, are involved in the biotransformation of imatinib. They could play a role in imatinib disposition in the targeted stem, progenitor and differentiated cancer cells, with a possible contribution of the metabolites toward the activity of the drug.